65,437 trials
Atrial Fibrillation
Primary: Number of Participants With Software's Rhythm Classification of SR in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG — 238 Participants…
Malaria
Primary: Number of Subjects With at Least One Occurrence of Plasmodium Falciparum (P. Falciparum) Parasitemia for Each Vaccination Schedule Versus Infectivity Controls — 9; 5; 8…
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Serotype of the Parental Dengue Virus Strain Before and Following Injection (Inj.) With CYD Dengue Tetravalent…
Dengue Fever · Dengue Hemorrhagic Fever
Primary: Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine…
Maternal Death · Neonatal Death
Primary: Maternal Postnatal Care Referral — 0.044; 0.154 proportion of maternal clients referred
Multiple Sclerosis
Primary: Depression Measured With the Patient Health Questionnaire 9 (PHQ-9) Scale — 5.2; 4.6 units on a scale
Bipolar Disorder
Primary: Inpatient Hospitalizations Among Bipolar Patients — 0.17; 0.17 hospitalizations per year
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
Smoking Cessation
Primary: Number of Participants With Smoking Abstinence at Month 6 — 47; 13 Participants
Parkinson's Disease
Primary: Change From Baseline on Cognitive Section of Alzheimer Disease Assessment Scale (ADAS-Cog) at Month 6 — -0.24; 0.95 score on a scale — p=0.2
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score in 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24 Post-randomization — 0.538; -0.075 Score on a scale…
Breast Cancer
Primary: Accuracy of %Change in TOI Between Baseline and Mid-therapy to Predict Pathologic Response (pCR +/-) — 0.60 probability — p=0.059
Narcolepsy
Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 2.12; 4.74; 9.77; 12.27 minutes
GIST
Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Primary: Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 4; 3; 4 Participants